NCT06987643 - A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

June 28, 2026

Conditions

Moderate to Severe Acute Ischaemic StrokeIschaemic Stroke

Interventions

DRUG

Neflamapimod

Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules

DRUG

Placebo

Placebo is a capsule that looks just like neflamapimod but without the active ingredients

Trial Locations (11)

RECRUITING

Campbelltown Hospital, Campbelltown

RECRUITING

Liverpool Hospital, Liverpool

RECRUITING

Sunshine Coast University Hospital, Birtinya

RECRUITING

Gold Coast University Hospital, Southport

RECRUITING

Box Hill Hospital, Box Hill

NOT_YET_RECRUITING

Monash Medical Centre, Clayton

NOT_YET_RECRUITING

St Vincent's Hospital Melbourne, Fitzroy

RECRUITING

Austin Hospital, Heidelberg

RECRUITING

Alfred Hospital, Melbourne

RECRUITING

Royal Melbourne Hospital, Melbourne

RECRUITING

Western Health- Sunshine Hospital, St Albans